Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations

NCT06299371 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.

NCT NCT06299371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations
Lead sponsor
Liaoning Cancer Hospital & Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 15, 2024
Completion date
April 15, 2029
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer